Predictive Oncology Inc. (POAI) Financial Ratios
17 years of historical data (2008–2024) · Healthcare · Medical - Instruments & Supplies
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
N/A
—
5yr avg: 27.17
30Y Low10.0·High128.4
ROE
↑
-302.4%
↑-60% vs avg
5yr avg: -188.7%
30Y Low-429%·High-83%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
POAI Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Predictive Oncology Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $27M | $67M | $198M | $339M | $784M | $131M | $112M | $119M | $96M | $119M | $3.4B |
| Enterprise Value | $28M | $68M | $192M | $318M | $756M | $136M | $118M | $120M | $96M | $117M | $3.4B |
| P/E Ratio → | -2.19 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 16.49 | 41.31 | 121.73 | 225.50 | 551.59 | 104.78 | 79.60 | 84.30 | 147.21 | 259.73 | 5261.84 |
| P/B Ratio | — | — | 23.95 | 15.60 | 19.46 | 49.65 | 10.00 | 2225.40 | 35.81 | 128.36 | 837.19 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
POAI EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 42.17 | 118.04 | 210.96 | 532.35 | 108.93 | 83.74 | 85.34 | 146.04 | 255.87 | 5254.42 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
POAI Profitability
Margins and return-on-capital ratios measuring operating efficiency
Predictive Oncology Inc. earns an operating margin of -673.7%. Operating margins have expanded from -1729.3% to -673.7% over the past 3 years, signaling improving operational efficiency. A negative ROE of -302.4% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 49.1% | 49.1% | 62.6% | 66.4% | 65.7% | 64.3% | 62.3% | 70.5% | 77.4% | 60.2% | 53.5% |
| Operating Margin | -673.7% | -673.7% | -744.5% | -1729.3% | -1437.9% | -2025.1% | -1604.2% | -556.9% | -1183.0% | -1429.6% | -672.4% |
| Net Profit Margin | -751.4% | -751.4% | -859.1% | -1709.6% | -1383.6% | -2067.0% | -1373.7% | -714.5% | -1183.0% | -1429.6% | -732.1% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -302.4% | -302.4% | -93.1% | -83.0% | -91.6% | -373.1% | -343.7% | -734.8% | -428.5% | -259.2% | -116.5% |
| ROA | -125.9% | -125.9% | -69.7% | -74.1% | -69.2% | -146.1% | -148.7% | -275.1% | -240.9% | -154.6% | -146.6% |
| ROIC | -473.8% | -473.8% | -847.8% | -304.7% | -147.5% | -152.7% | -182.7% | -341.6% | -1070.6% | — | — |
| ROCE | -184.7% | -184.7% | -75.0% | -83.5% | -92.3% | -333.1% | -391.9% | -572.7% | -394.7% | -244.1% | -107.0% |
POAI Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $1M ($2M total debt minus $734673 cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.33 | 0.01 | 0.02 | 2.22 | 0.53 | 30.58 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | -0.73 | -1.01 | -0.68 | 1.97 | 0.52 | 27.54 | -0.28 | -1.91 | -1.18 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | -2.44 | — | — | — | — | — | -999999.00 | -11.26 |
POAI Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.62x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 6.02x to 0.62x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.62 | 0.62 | 2.55 | 6.02 | 9.09 | 0.16 | 0.07 | 0.40 | 2.54 | 1.66 | 3.55 |
| Quick Ratio | 0.51 | 0.51 | 2.43 | 5.91 | 8.97 | 0.13 | 0.06 | 0.33 | 2.26 | 1.48 | 3.40 |
| Cash Ratio | 0.20 | 0.20 | 2.21 | 5.68 | 8.70 | 0.07 | 0.01 | 0.04 | 0.82 | 1.30 | 3.20 |
| Asset Turnover | — | 0.33 | 0.11 | 0.06 | 0.03 | 0.10 | 0.06 | 0.38 | 0.18 | 0.16 | 0.12 |
| Inventory Turnover | 2.14 | 2.14 | 1.27 | 1.17 | 1.26 | 1.54 | 2.80 | 1.72 | 0.56 | 0.67 | 1.31 |
| Days Sales Outstanding | — | 167.59 | 62.26 | 80.30 | 91.00 | 74.87 | 76.81 | 188.72 | 448.71 | 31.12 | 21.35 |
POAI Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Predictive Oncology Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $5M | $4M | $4M | $3M | $597510 | $143505 | $64080 | $31815 | $14115 | $15615 |
Peer Comparison
Compare POAI with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 POAIYou | $27M | -2.2 | — | — | 49.1% | -673.7% | -302.4% | -473.8% | — |
 RXRX | $1B | -2.3 | — | — | -62.0% | -867.9% | -59.5% | -95.8% | — |
 ABSI | $894M | -6.8 | — | — | -319.4% | -4454.2% | -62.5% | -58.0% | — |
 SDGR | $992M | -9.4 | — | 79.7 | 55.7% | -65.2% | -26.3% | -39.4% | — |
 ACLX | $7B | -28.3 | — | — | 70.0% | -1135.6% | -53.4% | -46.2% | — |
 CDNA | $1B | -53.6 | — | 30.7 | 67.0% | -5.5% | -6.3% | -5.7% | — |
 NTRA | $31B | -144.6 | — | 285.5 | 64.8% | -13.4% | -14.3% | -36.1% | — |
 EXAS | $20B | -95.4 | — | 56.1 | 69.7% | -6.4% | -8.7% | -3.6% | — |
 VCYT | $3B | 49.7 | 30.7 | 25.7 | 69.6% | 14.3% | 5.3% | 5.6% | 0.4 |
 ILMN | $21B | 25.5 | 19.6 | 22.6 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
 TMO | $176B | 26.8 | 19.0 | 28.0 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 17 years · Updated daily
See POAI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs POAI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare POAI vs RXRX
Side-by-side business, growth, and profitability comparison vs Recursion Pharmaceuticals, Inc..
Start ComparisonPOAI — Frequently Asked Questions
Quick answers to the most common questions about buying POAI stock.
What is Predictive Oncology Inc.'s P/E ratio?
Predictive Oncology Inc.'s current P/E ratio is -2.2x. This places it at the 50th percentile of its historical range.
What is Predictive Oncology Inc.'s ROE?
Predictive Oncology Inc.'s return on equity (ROE) is -302.4%. The historical average is -232.3%.
Is POAI stock overvalued?
Based on historical data, Predictive Oncology Inc. is trading at a P/E of -2.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Predictive Oncology Inc.'s profit margins?
Predictive Oncology Inc. has 49.1% gross margin and -673.7% operating margin.